既往癌症对局限性胰腺神经内分泌肿瘤患者的生存结果有影响吗?

Your Location：

Home >

Browse articles >

既往癌症对局限性胰腺神经内分泌肿瘤患者的生存结果有影响吗?

中国医学科学杂志（英文版） 2021年36卷第4期页码：284-294

Original Articles | Updated：2024-04-10

|

- 既往癌症对局限性胰腺神经内分泌肿瘤患者的生存结果有影响吗?
- Affiliations：
  
  Department of General Surgery, Peking University Third Hospital, Beijing 100191, China
- Author bio：
  
  *Hangyan Wang, E-mail: wanghangyan111@163.com;
  Chunhui Yuan, Tel: 86-10-82267321, Fax: 86-10-62010334, E-mail: yuanchunhui1971@163.com;
  Dianrong Xiu, Tel: 86-10-82267320, Fax: 86-10-62010334, E-mail: xiudianrong1964@163.com
- Funds：
  
  National Natural Science Foundation of China-Youth Fund(81702855);National Natural Science Foundation of China(81672862)
- DOI：10.24920/003803
  中图分类号：
- 收稿日期：2020-07-09，
  
  网络出版日期：2021-10-08，
  
  纸质出版日期：2021-12-31
- Accepted：
Scan QR Code
王亮, 李刚, 邴运韬, 等. 既往癌症对局限性胰腺神经内分泌肿瘤患者的生存结果有影响吗?[J]. 中国医学科学杂志（英文版）, 2021,36(4):284-294.

Wang Liang, Li Gang, Bing Yun-tao, et al. Does Prior Cancer Have an Influence on the Survival Outcomes of Patients with Localized Pancreatic Neuroendocrine Tumors?[J]. Chinese medical sciences journal, 2021, 36(4): 284-294.
王亮, 李刚, 邴运韬, 等. 既往癌症对局限性胰腺神经内分泌肿瘤患者的生存结果有影响吗?[J]. 中国医学科学杂志（英文版）, 2021,36(4):284-294. DOI： 10.24920/003803.

Wang Liang, Li Gang, Bing Yun-tao, et al. Does Prior Cancer Have an Influence on the Survival Outcomes of Patients with Localized Pancreatic Neuroendocrine Tumors?[J]. Chinese medical sciences journal, 2021, 36(4): 284-294. DOI： 10.24920/003803.

摘要

目的

探讨既往非胰腺来源的恶性肿瘤对局限性胰腺神经内分泌肿瘤（PanNET）患者生存结局的影响。

方法

我们选取美国肿瘤监测、流行病学和生存结果数据库（the Surveillance

Epidemiology

and End Results database

SEER database）中

1973年至2015年期间诊断为局部PanNET的患者进行研究。根据患者既往是否存在非胰腺恶性肿瘤

我们将患者分为两组。在倾向评分匹配前和匹配后

我们比较了两组患者的临床病理特征

并研究了总体生存率和癌症特异性生存率的独立影响因素。

结果

在2778例局限性PanNET患者中

357例（12.9%）既往曾患有癌症。在2778例患者中

数据资料完整的患者有1344例

其中既往无肿瘤病史的患者1211例

合并肿瘤病史的患者133例。分析发现

既往患有癌症与高龄（65岁以上

57.9%既往患有癌症

31.0%既往无癌症

P

<

0.001）、诊断年份较晚（87.2%比80.2%

P

=0.049）、低分化/未分化级别肿瘤比例较高（4.5%比1.5%

P

=0.025）和既往肿瘤未手术比例较高（19.5%比10.4%

P

=0.003）相关。前列腺癌（29.32%）、乳腺癌（18.05%）、其他泌尿生殖道癌和腹膜后癌（16.54%）以及胃肠道癌（12.78%）是最常见的既往癌症类型。大多数既往癌症（95.49%）为局限性或区域性肿瘤

只有4.51%的患者既往癌症伴远处转移。两个肿瘤发病间隔时间≤36个月、36-60个月、60-120个月和

>

120个月分别占33.08%、13.53%、24.06%和29.32%。在对两组患者变量进行倾向评分匹配前和匹配后

我们对患者进行了单变量和多变量Cox比例风险分析

结果显示匹配前和匹配后

既往癌症的存在与否并不影响局部PanNET患者的生存结果。进一步亚组分析显示

既往合并转移癌症的患者PanNET特异性生存率比既往局部或区域癌症的患者或既往无癌症的患者生存率低。既往癌症的部位和两种肿瘤的间隔期不影响患者的生存率。

结论

具有既往癌症史的局限性PanNET患者的生存结果与无既往癌症史的患者相当。如果其他条件相同

则具有既往癌症史的局限性PanNET患者可以作为临床试验的候选患者。此研究结果支持为此类患者的PanNET提供更为积极的治疗方法。

Abstract

Objective

To investigate the impact of prior non-pancreatic cancer on the survival outcomes of patients with localized pancreatic neuroendocrine tumors (PanNETs).

Methods

We reviewed the Surveillance

Epidemiology

and End Results database and selected patients with localized PanNETs diagnosed between 1973 and 2015. We divided the patients into two groups according to the presence or absence of prior non-pancreatic malignancy. Before and after propensity score matching

we compared the clinicopathological characteristics and studied the overall survival and cancer-specific survival.

Results

A total of 357 (12.9%) of 2778 patients with localized PanNETs had prior cancer. A total of 1211 cases with only a localized PanNET and 133 cases with a localized PanNET and prior cancer had complete data and met the inclusion criteria of the current study. Patients with prior cancer were associated with advanced age (

>

65 years

57.9% prior cancer

vs

. 31.0% no prior cancer

P

<

0.001)

later year of diagnosis (87.2%

vs

. 80.2%

P

=0.049)

a higher proportion of poorly differentiated/undifferentiated grade tumors (4.5%

vs

. 1.5%

P

=0.025)

and a higher proportion of no primary site surgery (19.5%

vs

. 10.4%

P

=0.003). Prostate (29.32%)

breast (18.05%)

other genitourinary and retroperitoneal (16.54%)

and gastrointestinal (12.78%) cancers were the most common prior cancer types. Most of the prior cancers (95.49%) were localized and regional

and only 4.51% of the prior cancers were distant. Patients with interval periods between the prior cancer and PanNET of ≤36 months

36-60 months

60-120 months

and

>

120 months accounted for 33.08%

13.53%

24.06%

and 29.32% of all cases with prior cancers

respectively. Univariate and multivariate

Cox

proportional hazards analyses were performed. The presence/absence of prior cancers did not impact survival outcomes of patients with localized PanNETs before and after propensity score matching (PSM). Further subgroups analysis showed that

patients with localized PanNETs and prior distant cancer had worse cancer-specific survival than patients with prior local/regional cancer or patients without prior cancer (

P

<

0.001). No significant differences in cancer-specific survival were observed in terms of the different sites of the prior cancers and the different interval periods of prior cancers and PanNETs (

P

<

0.05).

Conclusions

Patients with localized PanNETs and a history of prior cancer had survival outcomes that were comparable to those of patients with no history of prior cancer. Patients with localized PanNETs and prior cancer could be candidates for clinical trials if they satisfy all other conditions; aggressive and potentially curative therapies should be offered to these patients.

关键词

Keywords

references

Halfdanarson TR , Rabe KG , Rubin J , et al . Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival . Ann Oncol 2008 ; 19 ( 10 ): 1727 - 33 . doi: 10.1093/annonc/mdn351 https://dx.doi.org/10.1093/annonc/mdn351 . DOI: 10.1093/annonc/mdn351 http://doi.org/10.1093/annonc/mdn351

Lepage C , Bouvier AM , Phelip JM , et al . Incidence and management of malignant digestive endocrine tumours in a well defined French population . Gut 2004 ; 53 ( 4 ): 549 - 53 . doi: 10.1136/gut.2003.026401 https://dx.doi.org/10.1136/gut.2003.026401 . DOI: 10.1136/gut.2003.026401 http://doi.org/10.1136/gut.2003.026401

Yao JC , Hassan M , Phan A , et al . One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States . J Clin Oncol 2008 ; 26 ( 18 ): 3063 - 72 . doi: 10.1200/JCO.2007.15.4377 https://dx.doi.org/10.1200/JCO.2007.15.4377 . DOI: 10.1200/JCO.2007.15.4377 http://doi.org/10.1200/JCO.2007.15.4377 http://ascopubs.org/doi/10.1200/JCO.2007.15.4377 http://ascopubs.org/doi/10.1200/JCO.2007.15.4377

Das S , Dasari A . Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? . Curr Oncol Rep 2021 ; 23 ( 4 ): 43 . doi: 10.1007/s11912-021-01029-7 https://dx.doi.org/10.1007/s11912-021-01029-7 . DOI: 10.1007/s11912-021-01029-7 http://doi.org/10.1007/s11912-021-01029-7 https://doi.org/10.1007/s11912-021-01029-7 https://doi.org/10.1007/s11912-021-01029-7

Dasari A , Shen C , Halperin D , et al . Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States . JAMA Oncol 2017 ; 3 ( 10 ): 1335 - 42 . doi: 10.1001/jamaoncol.2017.0589 https://dx.doi.org/10.1001/jamaoncol.2017.0589 . DOI: 10.1001/jamaoncol.2017.0589 http://doi.org/10.1001/jamaoncol.2017.0589 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.0589 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.0589

Bilimoria KY , Tomlinson JS , Merkow RP , et al . Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9, 821 patients . J Gastrointest Surg 2007 ; 11 ( 11 ):1460-7; discussion 1467 - 9 . doi: 10.1007/s11605-007-0263-3 https://dx.doi.org/10.1007/s11605-007-0263-3 . DOI: 10.1007/s11605-007-0263-3 http://doi.org/10.1007/s11605-007-0263-3

Donin N , Filson C , Drakaki A , et al . Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008 . Cancer 2016 ; 122 ( 19 ): 3075 - 86 . doi: 10.1002/cncr.30164 https://dx.doi.org/10.1002/cncr.30164 . DOI: 10.1002/cncr.30164 http://doi.org/10.1002/cncr.30164 http://doi.wiley.com/10.1002/cncr.v122.19 http://doi.wiley.com/10.1002/cncr.v122.19

Michaud DS , Giovannucci E , Willett WC , et al . Physical activity, obesity, height, and the risk of pancreatic cancer . JAMA 2001 ; 286 ( 8 ): 921 - 9 . doi: 10.1001/jama. 286.8.921 https://dx.doi.org/10.1001/jama. 286.8.921 . DOI: 10.1001/jama. 286.8.921 http://doi.org/10.1001/jama. 286.8.921 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.286.8.921 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.286.8.921

Olson SH , Kurtz RC . Epidemiology of pancreatic cancer and the role of family history . J Clin Oncol 2013 ; 107 ( 1 ): 1 - 7 . doi: 10.1002/jso.23149 https://dx.doi.org/10.1002/jso.23149 . DOI: 10.1002/jso.23149 http://doi.org/10.1002/jso.23149 https://linkinghub.elsevier.com/retrieve/pii/S0959804918314588 https://linkinghub.elsevier.com/retrieve/pii/S0959804918314588

Shahar T , Nossek E , Steinberg DM , et al . The impact of enrollment in clinical trials on survival of patients with glioblastoma . J Clin Neurosci 2012 ; 19 ( 11 ): 1530 - 34 . doi: 10.1016/j.jocn.2012.04.005 https://dx.doi.org/10.1016/j.jocn.2012.04.005 . DOI: 10.1016/j.jocn.2012.04.005 http://doi.org/10.1016/j.jocn.2012.04.005

Laccetti AL , Pruitt SL , Xuan L , et al . Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual . J Natl Cancer Inst 2015 ; 107 ( 4 ):djv002. doi: 10.1093/jnci/djv002 https://dx.doi.org/10.1093/jnci/djv002 . DOI: 10.1093/jnci/djv002 http://doi.org/10.1093/jnci/djv002

Laccetti AL , Pruitt SL , Xuan L , et al . Prior cancer does not adversely affect survival in locally advanced lung cancer: a national SEER-medicare analysis . Lung Cancer 2016 ; 98 : 106 - 13 . doi: 10.1016/j. lungcan.2016.05.029 https://dx.doi.org/10.1016/j. lungcan.2016.05.029 . DOI: S0169-5002(16)30355-5 http://doi.org/S0169-5002(16)30355-5

Al-Husseini MJ , Saad AM , El-Shewy KM , et al . Prior malignancy impact on survival outcomes of glioblastoma multiforme; population-based study . Int J Neurosci 2019 ; 129 ( 5 ): 447 - 54 . doi: 10.1080/00207454.2018.1538989 https://dx.doi.org/10.1080/00207454.2018.1538989 . DOI: 10.1080/00207454.2018.1538989 http://doi.org/10.1080/00207454.2018.1538989

Duhamel A , Labreuche J , Gronnier C , et al . Statistical tools for propensity score matching . Ann Surg 2017 ; 265 ( 6 ): E79 - e80 . doi: 10.1097/sla.0000000000001312 https://dx.doi.org/10.1097/sla.0000000000001312 . DOI: 10.1097/sla.0000000000001312 http://doi.org/10.1097/sla.0000000000001312 https://journals.lww.com/00000658-201706000-00041 https://journals.lww.com/00000658-201706000-00041

Morgan CJ . Reducing bias using propensity score matching . J Nucl Cardiol 2018 ; 25 ( 2 ): 404 - 6 . doi: 10.1007/s12350-017-1012-y https://dx.doi.org/10.1007/s12350-017-1012-y . DOI: 10.1007/s12350-017-1012-y http://doi.org/10.1007/s12350-017-1012-y http://link.springer.com/10.1007/s12350-017-1012-y http://link.springer.com/10.1007/s12350-017-1012-y

Li G , Tian ML , Bing YT , et al . Impact of a prior nonpancreatic malignancy on survival outcomes of patients with stage Ⅳ pancreatic neuroendocrine tumor: a population-based and propensity score matching study . Pancreas 2020 ; 49 ( 8 ): 1090 - 8 . doi: 10.1097/MPA.0000000000001630 https://dx.doi.org/10.1097/MPA.0000000000001630 . DOI: 10.1097/MPA.0000000000001630 http://doi.org/10.1097/MPA.0000000000001630 https://journals.lww.com/10.1097/MPA.0000000000001630 https://journals.lww.com/10.1097/MPA.0000000000001630

Shen M , Boffetta P , Olsen JH , et al . A pooled analysis of second primary pancreatic cancer . Am J Epidemiol 2006 ; 163 ( 6 ): 502 - 11 . doi: 10.1093/aje/kwj073 https://dx.doi.org/10.1093/aje/kwj073 . DOI: 10.1093/aje/kwj073 http://doi.org/10.1093/aje/kwj073

Sara JS , Lindsay MM , Amy B , et al . Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000-2015 . Cancer Epidemiol 2020 ; 64 : 101664 . doi: 10.1016/j.canep.2019.101664 https://dx.doi.org/10.1016/j.canep.2019.101664 . DOI: 10.1016/j.canep.2019.101664 http://doi.org/10.1016/j.canep.2019.101664 https://linkinghub.elsevier.com/retrieve/pii/S1877782119301742 https://linkinghub.elsevier.com/retrieve/pii/S1877782119301742

Sung H , Hyun N , Leach CR , et al . Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in the United States . JAMA 2020 ; 324 ( 24 ): 2521 - 35 . doi: 10.1001/jama.2020.23130 https://dx.doi.org/10.1001/jama.2020.23130 . DOI: 10.1001/jama.2020.23130 http://doi.org/10.1001/jama.2020.23130 https://jamanetwork.com/journals/jama/fullarticle/2774406 https://jamanetwork.com/journals/jama/fullarticle/2774406

Ross S , Grant A , Counsell C , et al . Barriers to participation in randomised controlled trials: a systematic review . J Clin Epidemiol 1999 ; 52 ( 12 ): 1143 - 56 .

Al-Husseini MJ , Saad AM , Turk T , et al . Impact of prior malignancy on survival outcomes of stage Ⅳ pancreatic adenocarcinoma: SEER-Based Cohort . J Gastrointest cancer 2018 ; 50 ( 4 ): 794 - 800 . doi: 10.1007/s12029-018-0158-4 https://dx.doi.org/10.1007/s12029-018-0158-4 . DOI: 10.1007/s12029-018-0158-4 http://doi.org/10.1007/s12029-018-0158-4 https://doi.org/10.1007/s12029-018-0158-4 https://doi.org/10.1007/s12029-018-0158-4

Jennifer LG . Inherited syndromes involving pancreatic neuroendocrine tumors . J Gastrointest Oncol 2020 ; 11 ( 3 ): 559 - 66 . doi: 10.21037/jgo.2020.03.09 https://dx.doi.org/10.21037/jgo.2020.03.09 . DOI: 10.21037/jgo.2020.03.09 http://doi.org/10.21037/jgo.2020.03.09

Oberg K . The genetics of neuroendocrine tumors . Semin Oncol 2013 ; 40 ( 1 ): 37 - 44 . doi: 10.1053/j.seminoncol.2012.11.005 https://dx.doi.org/10.1053/j.seminoncol.2012.11.005 . DOI: 10.1053/j.seminoncol.2012.11.005 http://doi.org/10.1053/j.seminoncol.2012.11.005 https://linkinghub.elsevier.com/retrieve/pii/S0093775412002047 https://linkinghub.elsevier.com/retrieve/pii/S0093775412002047

0

浏览量

391

Downloads

0

CSCD

>

文章被引用时，请邮件提醒。

Submit

关联资源

相关文章

Using a Nomogram to Preoperatively Predict Distant Metastasis of Pancreatic Neuroendocrine Tumor in Elderly Patients

相关作者

邴运韬

田茂霖

原春辉

相关机构

暂无数据

⁰